The World Health Organization (WHO) has released an evidence-informed guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the

“A Healthy People 2030 objective is to reduce the proportion of US adults with obesity. The baseline in 2013–2016 was

Semaglutide 2.4 mg is associated with improved insulin sensitivity and glycemic outcomes among adolescents with obesity, according to study findings

The American Heart Association (AHA) advises that clinicians follow a “5A model” when implementing obesity science into clinical practice, according

Obesity bias has a negative impact on medical decision making and quality of care, according to results of a systematic